tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Feb 3;223(2):192-196.
doi: 10.1093/infdis/jiaa610.
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Rehabilitation Facility: Evolution of the Presence of Nasopharyngeal SARS-CoV-2 and Serological Antibody Responses
Benjamin H L Harris[SUP] 1 2 [/SUP], Mohamed Zuhair[SUP] 1 3 [/SUP], Matteo Di Giovannantonio[SUP] 2 [/SUP], Carolina Rosadas[SUP] 3 [/SUP], Maryam Khan[SUP] 3 [/SUP], Charlotte-Eve Short[SUP] 3 [/SUP], Thilipan Thaventhiran[SUP] 3 [/SUP], Rachael Quinlan[SUP] 3 [/SUP], Andrew Taylor[SUP] 4 [/SUP], Ronan Calvez[SUP] 4 [/SUP], Graham P Taylor[SUP] 3 [/SUP], Richard S Tedder[SUP] 3 [/SUP], Myra O McClure[SUP] 3 [/SUP], Michael Fertleman[SUP] 5 [/SUP]
Affiliations
Abstract
At the start of the UK coronavirus disease 2019 epidemic, this rare point prevalence study revealed that one-third of patients (15 of 45) in a London inpatient rehabilitation unit were found to be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but asymptomatic. We report on 8 patients in detail, including their clinical stability, the evolution of their nasopharyngeal viral reverse-transcription polymerase chain reaction (RT-PCR) burden, and their antibody levels over time, revealing the infection dynamics by RT-PCR and serology during the acute phase. Notably, a novel serological test for antibodies against the receptor binding domain of SARS-CoV-2 showed that 100% of our asymptomatic cohort remained seropositive 3-6 weeks after diagnosis.
Keywords: COVID-19; Imperial Hybrid DABA; SARS-CoV-2; SARS-CoV-2 receptor binding domain (RBD); anti-NP; anti-RBD; antibodies to nucleoprotein; asymptomatic.
. 2021 Feb 3;223(2):192-196.
doi: 10.1093/infdis/jiaa610.
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Rehabilitation Facility: Evolution of the Presence of Nasopharyngeal SARS-CoV-2 and Serological Antibody Responses
Benjamin H L Harris[SUP] 1 2 [/SUP], Mohamed Zuhair[SUP] 1 3 [/SUP], Matteo Di Giovannantonio[SUP] 2 [/SUP], Carolina Rosadas[SUP] 3 [/SUP], Maryam Khan[SUP] 3 [/SUP], Charlotte-Eve Short[SUP] 3 [/SUP], Thilipan Thaventhiran[SUP] 3 [/SUP], Rachael Quinlan[SUP] 3 [/SUP], Andrew Taylor[SUP] 4 [/SUP], Ronan Calvez[SUP] 4 [/SUP], Graham P Taylor[SUP] 3 [/SUP], Richard S Tedder[SUP] 3 [/SUP], Myra O McClure[SUP] 3 [/SUP], Michael Fertleman[SUP] 5 [/SUP]
Affiliations
- PMID: 33535238
- PMCID: PMC7665566
- DOI: 10.1093/infdis/jiaa610
Abstract
At the start of the UK coronavirus disease 2019 epidemic, this rare point prevalence study revealed that one-third of patients (15 of 45) in a London inpatient rehabilitation unit were found to be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but asymptomatic. We report on 8 patients in detail, including their clinical stability, the evolution of their nasopharyngeal viral reverse-transcription polymerase chain reaction (RT-PCR) burden, and their antibody levels over time, revealing the infection dynamics by RT-PCR and serology during the acute phase. Notably, a novel serological test for antibodies against the receptor binding domain of SARS-CoV-2 showed that 100% of our asymptomatic cohort remained seropositive 3-6 weeks after diagnosis.
Keywords: COVID-19; Imperial Hybrid DABA; SARS-CoV-2; SARS-CoV-2 receptor binding domain (RBD); anti-NP; anti-RBD; antibodies to nucleoprotein; asymptomatic.